My take on today’s events and 10-Q filing is that IPIX has ample funding through 2021 which positions IPIX from a position of strength in partnership discussions with government agencies and/or BP. 120 patient B-CV19 FDA trial is underway and successful results will dramatically increase the value of IPIX. Any extensions to overseas portion of CV19 trials are likely positive opportunities and are likely separate from fixed FDA sponsored 120 patient trial. Today’s “trading” is simply more of the same criminal manipulation (see post # 68049. Criminally controlled share price and phony volume. Rinse and repeat.)

Key points from 10-Q:

As of December 31, 2020, IPIX had approximately $8.2 million in cash compared to $6.0 million of cash as of June 30, 2020, and as of the date of this filing (2/22/21), have approximately $13.9 million in cash.

Leo says they expect to have sufficient funds for the year.

Outstanding Share (OS) total as of 2/10/21 is 418,069,575

Clinical Studies cost was $2.981M in 3 month period ending 12/31/21

A grant application for federally-funded research is pending, and further grant applications are planned.

A Phase 2 clinical trial in B-IBD UC patients and is anticipated to begin in 2021, pending completion of drug formulation work and securing sufficient drug supply and working capital.

Details of the KIPS Bay Select LP deal were detailed which added $5M to IPIX’s cash position.